Initial Clinical Results of a Novel Immuno-PET Theranostic Probe in Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer

Conclusion: Immuno-PET using anti-CEA/anti-IMP288 bispecific antibody, followed by 68Ga-IMP288, is a potentially sensitive theranostic imaging method for HER2-negative, CEA-positive metastatic breast cancer patients and warrants further research.

Source: Journal of Nuclear Medicine - August 2, 2020 Category: Nuclear Medicine Authors: Rousseau, C., Goldenberg, D. M., Colombie, M., Sebille, J.-C., Meingan, P., Ferrer, L., Baumgartner, P., Cerato, E., Masson, D., Campone, M., Rauscher, A., Fleury, V., Labbe, C., Chauvet, A. F., Fresnel, J.-S., Toquet, C., Barbet, J., Sharkey, R. M., Camp Tags: Clinical Source Type: research